FDA Warning Letter Blasts Mylan’s Lax API Impurity Controls
Cites Equipment Cleaning And Monitoring Of Recovered Solvents For Impurities
Concerned about another possible nitrosamine scare, the US FDA has sent a warning letter to Mylan focusing on the firm’s failure to control contamination risks of its APIs and inadequate testing of reused solvents.
